Assessment of therapeutic pathomorphosis after neoadjuvant therapy of HER2-positive breast cancer

In Kazakhstan, the incidence and mortality from breast cancer occupies the first place in the structure of the structure of all oncopathology and in the structure of oncological diseases in women. The purpose of the study: is to evaluate the immediate results of effectiveness at the level of one organization at the national level, using the example of the National Research Oncology Center. Methods. The study included 30 patients with breast cancer who were treated at the chemotherapy center between 2021 and 2023, who received CT at the preoperative stage. Results. The analysis showed that 15 patients receiving double blockade had grade IV pathomorphosis (50%). In 6 cases, pathomorphosis of the III degree (20%) was noted, in 5 cases – pathomorphosis of the II degree (16,6%), in 2 cases – pathomorphosis of the I degree (6,6%). In 2 patients, the cancer process progressed against the background of the treatment, and bone metastasis in both cases. Conclusions. The study shows that the implementation of neoadjuvant therapy with double blockade in breast cancer leads to complete regression of the tumor. Key words: breast cancer, Her2 - positive type, neoadjuvant drug therapy, therapeutic pathomorphosis, tumor regression.